Entrada TherapeuticsTRDA +3.36%23 PB Ratio is 1.06 as of Jun. 26, 2026, which is 30% below its 10-year median of 1.52. GuruFocus rates TRDA with a GF Score™ of 23/100 and a GF Value™ of $0.92 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,232 Biotechnology companies, Entrada Therapeutics ranks better than 81.57% on this metric.
The historical rank and industry rank for Entrada Therapeutics's PB Ratio or its related term are showing as below:
TRDA'
s PB Ratio Range Over the Past 10 Years
Min: 0.52 Med: 1.52 Max: 2.77
Current: 1.06
During the past 7 years, Entrada Therapeutics's highest PB Ratio was 2.77. The lowest was 0.52. And the median was 1.52.
TRDA's PB Ratio is ranked better than 81.57% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs TRDA: 1.06
During the past 12 months, Entrada Therapeutics's average Book Value Per Share Growth Rate was -36.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.70% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Entrada Therapeutics was 6.00% per year. The lowest was 5.70% per year. And the median was 5.85% per year.
Back to Basics: PB Ratio
Entrada Therapeutics (NAS:TRDA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Entrada Therapeutics PB Ratio Related Terms
Entrada Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Entrada Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entrada Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Entrada Therapeutics (TRDA) has a PB Ratio of 1.06 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Entrada Therapeutics and its competitors. This is 30% below median its historical median of 1.52. Over the past decade, Entrada Therapeutics' PB Ratio has ranged from 0.52 to 2.77. According to the industry distribution chart, Entrada Therapeutics ranks #227 out of 1232 companies in the Biotechnology industry, placing it in the top 18.4%.
Is Entrada Therapeutics' PB Ratio too high?
Entrada Therapeutics' current PB Ratio of 1.06 is 30% below median its 10-year median of 1.52. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 2.77. The Biotechnology industry median PB Ratio is 2.80. Entrada Therapeutics' value of 1.06 is 62.1% below this industry median. Based on the distribution chart, Entrada Therapeutics ranks #227 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Entrada Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' PB Ratio compare to SABS and ACIU?
According to the Biotechnology industry distribution chart, Entrada Therapeutics ranks #227 out of 1232 companies for PB Ratio. This places Entrada Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Entrada Therapeutics' value of 1.06 is 62.1% below this benchmark. Historically, Entrada Therapeutics' own PB Ratio has ranged from 0.52 to 2.77 over the past decade. While the company's 10-year median is 1.52 vs. the industry median of 2.80, Entrada Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entrada Therapeutics's current PB Ratio of 1.06 is 62.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Entrada Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entrada Therapeutics's current PB Ratio is 1.06, which is 30% below median its own 10-year median of 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.92, compared to a current price of $7.38 — trading 702.2% above its estimated fair value. The current PB Ratio is 1.06, which is 30% below median its 10-year median of 1.52 and 62.1% below the Biotechnology industry median of 2.80. Entrada Therapeutics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current PB Ratio is 1.06 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entrada Therapeutics (TRDA) Overvalued in 2026?
Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued.
The current stock price of $7.38 is trading 702.2% above its estimated GF Value™ of $0.92.
GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.
Key valuation signals for TRDA:
PB Ratio: 1.06 (30% below median its 10-year median of 1.52)
GF Value™: $0.92 vs. price of $7.38 (702.2% above fair value)
Industry Position: 62.1% below the Biotechnology median (#227 of 1232)
No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
23GF Score
Get the complete analysis for TRDA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRDA has been successfully added to your 
